drugset / Trial / NCT01362205

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

NCT01362205 ↗

Phase 4 Terminated 49 enrolled Denver Health and Hospital Authority
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a prospective, randomized, double-blind, placebo-controlled, parallel-group study of dexmedetomidine versus placebo, with lorazepam rescue, for the management of severe alcohol withdrawal syndrome (AWS) and alcohol withdrawal delirium (AWD) in critically ill adults. The investigators hypothesize that the integration of dexmedetomidine (Precedex®) with usual therapy for the management of severe alcohol withdrawal syndrome (AWS) and alcohol withdrawal delirium/delirium tremens (AWD) in critically ill adult patients will reduce the time to resolution of AWS/AWD, increase the number of delirium-free and ventilator-free days in the first 28 days of hospitalization, reduce the length of ICU and hospital stays, and improve neurocognitive and quality of life scores on hospital discharge.

Timeline

Start
2012-03
Primary completion
2015-12
Completion
2016-09

Outcome

Missed primary endpoint

Stopped (Enrollment): “DSMB recommendation for slow enrollment”

registry analysis (other test); Dexmedetomidine vs Placebo; p = 0.2454; Wilcoxon (Mann-Whitney) NCT01362205 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 1.4 ug/kg —